Antigen News and Research

RSS

SARS-CoV-2 antibody response robust in nursing home residents after Pfizer-BioNTech vaccine

However, with the waning of the immune response, it is not clear if these older people respond to the vaccine as well as younger individuals do. A recent study explored this question and found that though the antibody levels were somewhat lower in this group, they were still robust. This is a promising observation.

26 Apr 2021

Recombinant protein vaccine fails expectations for SARS-CoV-2 neutralization

New interim results of a phase 1-2 clinical trial published in The Lancet Infectious Diseases tested the safety and effectiveness of an adjuvanted recombinant protein vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called CoV2 preS dTM.

26 Apr 2021

Potential new COVID vaccine from Australia

Phase 1 trial results published in The Lancet Infectious Diseases found a new subunit vaccine —an MF59-adjuvanted subunit vaccine using recombinant spike glycoprotein stabilized in a prefusion conformation by a novel molecular clamp — targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was safe and effective in producing an antigen-specific response in healthy adults.

26 Apr 2021

The Native Antigen Company Launches SARS-CoV-2 Neutralisation Assay Development Kit

The Native Antigen Company today announced the launch of its SARS-CoV-2 Neutralisation Assay Development Kit.

From The Native Antigen Company 23 Apr 2021

Striking difference identified between mRNA vaccination vs. SARS-CoV-2 infection immune responses

A team of scientists from the United States has recently compared the immune response elicited by natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination. Their findings reveal that, unlike vaccination, natural SARS-CoV-2 infection is associated with a robust interferon response together with an induction of cytotoxic gene expression in peripheral blood lymphocytes. The study is currently available on the medRxiv* preprint server.

22 Apr 2021

Changing the treatment paradigm for ‘cold’ tumors

Not all cancerous tumors are created equal. Some tumors, known as "hot" tumors, show signs of inflammation, which means they are infiltrated with T cells working to fight the cancer. Those tumors are easier to treat, as immunotherapy drugs can then amp up the immune response.

22 Apr 2021

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Researchers in the United States have developed adenovirus vectors that may be more effective at generating immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those used in the vaccines that are currently being rolled out to help combat the coronavirus disease 2019 (COVID-19) pandemic.

21 Apr 2021

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Researchers tested the antibodies elicited from mRNA vaccination and compared them to those from natural SARS-CoV-2 infection. They found the vaccine did not have antibodies to the virus nucleocapsid protein but had potent RBD antibodies.

21 Apr 2021

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Researchers identify differences in immune response in asymptomatic versus severe COVID-19 cases

The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those suffering a more serious reaction to the virus.

21 Apr 2021

Study identifies how SARS-CoV-2 enters and infects the brain

A recent preclinical study led by Anja Kipar of the University of Zurich and the University of Liverpool found evidence of the virus infecting and eventually provoking cell death in microglia and immune cells — but not neurons. The viral-induced apoptosis in these brain cells may explain why some long-haulers experience ‘brain fog’ months after recovery.

21 Apr 2021

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

A new study shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host cells. This finding could inform their use to treat symptomatic COVID-19.

20 Apr 2021

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

A recent review in the International Journal of Biological Macromolecules provides a novel overview of 'virosome'-based nanovaccine production, its properties, and its application in viral diseases, emphasizing its importance in SARS-CoV-2 vaccine discovery.

20 Apr 2021

Researchers manufacture the SARS-CoV-2 RBD in pichia

Researchers in the United States and India have developed a high-volume, low-cost platform for manufacturing vaccines to protect against different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

19 Apr 2021

New microfluidic system effectively isolates cancer spreading cells

The survival rate of cancer patients can drop to ten percent or less during metastasis, the spread of cancerous cells to create secondary tumors.

19 Apr 2021

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.

19 Apr 2021

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

A team of scientists in Germany recently evaluated the specificities and sensitivities of different serological assays for detecting antibodies against SARS-CoV-2.

19 Apr 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

Candidate coronavirus vaccines show promising results in early animal testing

A candidate vaccine that could provide protection against the COVID-19 virus and other coronaviruses has shown promising results in early animal testing.

17 Apr 2021

Rapid mRNA vaccination effectively controls SARS-CoV-2 transmission in long-term care facilities

Vaccine rollouts all over the world are aimed at cutting short the coronavirus disease 2019 (COVID-19) pandemic by inducing antibody-mediated immunity to the virus. A new study, recently released on the medRxiv* preprint server, addresses the successful reduction in viral spread and case incidence among residents of long-term care facilities (LTCF).

16 Apr 2021

Antigen News and Research

SARS-CoV-2 antibody response robust in nursing home residents after Pfizer-BioNTech vaccine

Recombinant protein vaccine fails expectations for SARS-CoV-2 neutralization

Potential new COVID vaccine from Australia

The Native Antigen Company Launches SARS-CoV-2 Neutralisation Assay Development Kit

Striking difference identified between mRNA vaccination vs. SARS-CoV-2 infection immune responses

Changing the treatment paradigm for ‘cold’ tumors

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Researchers identify differences in immune response in asymptomatic versus severe COVID-19 cases

Study identifies how SARS-CoV-2 enters and infects the brain

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

Researchers manufacture the SARS-CoV-2 RBD in pichia

New microfluidic system effectively isolates cancer spreading cells

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Candidate coronavirus vaccines show promising results in early animal testing

Rapid mRNA vaccination effectively controls SARS-CoV-2 transmission in long-term care facilities

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics